利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

107 条记录 (耗时 0.021 秒)

    A BINDING MOTIF OF A RECEPTOR
    102.
    发明公开
    A BINDING MOTIF OF A RECEPTOR 审中-公开
    REZEPTOR-BINDUNGSMOTIV

    公开(公告)号：EP1218404A4

    公开(公告)日：2004-04-07

    申请号：EP00963808

    申请日：2000-09-15

    申请人： MEDVET SCIENCE PTY LTD ,  BERNDT MICHAEL C

    发明人： GUTHRIDGE MARK ANDREW ,  STOMSKI FRANK CHARLES ,  LOPEZ ANGEL FRANCISCO

    IPC分类号： A61K38/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/71 ,  C07K14/715 ,  C07K2/00 ,  A61K38/17 ,  A61K38/19 ,  A61K38/20 ,  C07K7/06 ,  C07K14/705 ,  C07K14/72 ,  C12N9/16 ,  C12N15/12 ,  C12N15/52 ,  G01N33/50

    CPC分类号： C07K14/71 ,  A61K38/00 ,  C07K14/715

    摘要： The present invention relates to a binding motif of a receptor. In particular, the binding motif is a cytoplasmic domain associated with stimulation of receptor mediated activities. The present invention further contemplates methods of using the motif in particular for mediating activities of receptors. In one aspect of the present invention, there is provided a binding motif of a receptor capable of binding a cytoplasmic protein, said binding motif comprising an amino acid sequence wherein at least one amino acid is serine/threonine preferably there are at least two serines to indicate the cytoplasmic binding motif. Preferably the binding motif comprises an amino acid sequence including the sequence: -S-X-S/T- wherein the X is any amino acid.

    摘要翻译： 本发明涉及受体的结合基序。 特别地，结合基序是与受体介导的活性的刺激相关的细胞质结构域。 本发明进一步考虑了使用该基序特别是介导受体活性的方法。 在本发明的一个方面，提供了能够结合细胞质蛋白的受体的结合基序，所述结合基序包含氨基酸序列，其中至少一个氨基酸是丝氨酸/苏氨酸，优选至少有两个丝氨酸 表明细胞质结合基序。 优选地，结合基序包含包括以下序列的氨基酸序列：-S-X-S / T，其中X是任何氨基酸。

    Cytokine antagonists and agonists
    104.
    发明公开
    Cytokine antagonists and agonists 失效
    细胞因子拮抗剂非拮抗剂

    公开(公告)号：EP1386933A1

    公开(公告)日：2004-02-04

    申请号：EP03076937.6

    申请日：1997-01-29

    申请人： MEDVET SCIENCE PTY. LTD.

    发明人： Lopez, Angel, Hanson Center for Cancer Research ,  Bagley, Christopher, Hanson Centre for Cancer Res. ,  Woodcock, Joanna Hanson Center for Cancer Research

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2866 ,  A61K38/00 ,  C07K14/70503 ,  C07K14/715 ,  C07K14/7153 ,  C07K14/7155

    摘要： A therapeutic agent capable of binding to the F'-G' loop of domain 4 of the common β c chain of the receptor for GM-CSF, IL-3 and IL-5. The amino acid Tyr 421 which is located in the F'-G loop is critical in the high affinity binding and stimulation of function of GM-CSF, IL-3 and IL-5 to the common β c chain of their receptors. Other receptors for cytokines also show hydrophobic amino acids in analogous positions and it is probable that they too will play a pivotal role in binding of respective cytokines to them and in modulating function. Agents capable of binding to the F'-G' loops are suggested and should be of therapeutic value.

    摘要翻译： 能够结合GM-CSF，IL-3和IL-5受体的共同βc链的结构域4的F'-G'环的治疗剂。 位于F'-G环中的氨基酸Tyr <421>对于GM-CSF，IL-3和IL-5对其受体的常见β链的功能的高亲和力结合和刺激是至关重要的。 细胞因子的其他受体也显示类似位置的疏水性氨基酸，并且它们也可能在各自的细胞因子与它们的结合和调节功能中起关键作用。 提出能够结合F'-G'环的药剂，应具有治疗价值。

    MONOCLONAL ANTIBODY INHIBITOR OF GM-CSF, IL-3, IL-5 AND OTHER CYTOKINES, AND USES THEREOF
    105.
    发明公开
    MONOCLONAL ANTIBODY INHIBITOR OF GM-CSF, IL-3, IL-5 AND OTHER CYTOKINES, AND USES THEREOF 有权
    一种单克隆抗体，如GM-CSF的抑制剂，IL-3，IL-5和其它细胞因子及其用途

    公开(公告)号：EP1105426A4

    公开(公告)日：2002-03-27

    申请号：EP99941314

    申请日：1999-08-13

    申请人： MEDVET SCIENCE PTY LTD

    发明人： LOPEZ ANGEL ,  D ANDREA RICHARD

    IPC分类号： C07K16/28 ,  C07K16/24

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/73

    摘要： A method of isolating a monoclonal antibody capable of inhibiting any one of IL-3, GM-CSF and IL-5 binding to the common receptor beta c, or a monoclonal antibody capable of inhibiting the cytokines binding to a receptor analogous to beta c. The method includes the steps of immunising an animal with a cytokine receptor or portion of a cytokine containing the critical binding site which portion includes the extracellular domain 4 or analogous domain in the analogous common receptor or part thereof. Antibodies producing cells from the animal are then isolated and fused with a myeloma cell line and then screened for a cell line that produces an antibody of the desired type. A monoclonal antibody, or fragments thereof capable of inhibiting the binding of the cytokines IL-3, GM-CSF and IL-5 to the beta c receptor, and a hybridoma cell line producing the antibody are also claimed.